Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

Ruxolitinib is an FDA approved janus kinase (JAK)1/2 inhibitor used to treat myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera. We aimed to determine the metabolic consequences of ruxolitinib treatment in patients with MPNs. We performed a retrospective single-center...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapre, Manali, Tremblay, Douglas, Wilck, Eric, James, Annie, Leiter, Amanda, Coltoff, Alexander, Koshy, Anita G., Kremyanskaya, Marina, Hoffman, Ronald, Mascarenhas, John O., Gallagher, Emily J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851362/
https://www.ncbi.nlm.nih.gov/pubmed/31719581
http://dx.doi.org/10.1038/s41598-019-53056-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851362/
https://www.ncbi.nlm.nih.gov/pubmed/31719581
http://dx.doi.org/10.1038/s41598-019-53056-x

Ejemplares similares